Seems it may be important to continue herceptin after brain mets diagnosed

[Lani]

: Am J Clin Oncol. 2008 Jun;31(3):250-4. Links

Extended survival in women with brain metastases from HER2 overexpressing breast cancer.

Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, Blair P, Price CG.
Bristol Haematology and Oncology Centre, Bristol, UK. dchurch@doctors.org.uk
OBJECTIVES: Brain metastases (BM) are a significant complication of metastatic breast cancer (MBC). The high incidence of BM in HER2 overexpressing MBC is now well recognized, however, the optimal management of such patients is not yet clearly defined. We aimed to analyze factors affecting survival after diagnosis of BM in patients treated in our center. MATERIALS AND METHODS: Retrospective analysis of survival in all patients treated with antineoplastic therapy for BM from MBC in our institution between May 1st 2002 and April 30th 2005, according to HER2 expression and use of trastuzumab after diagnosis of BM. RESULTS: The median survival of the 26 patients with HER2 overexpressing disease after diagnosis of BM was significantly longer than that of the 60 patients with HER2 nonoverexpressing disease (6.2 vs. 3.8 months, P = 0.027). Further analysis revealed that this seems to be due to the favorable outcome of the 70% (n = 18) of HER2 overexpressing patients who received trastuzumab after BM were diagnosed. Median survival of this group was 11.9 months, compared with 3.8 months (HER2 nonoverexpressing disease, P = 0.002) and 3.0 months (HER2 overexpressing disease not treated with trastuzumab after development of BM, P = 0.05). CONCLUSION: Patients with HER2 overexpressing MBC who received trastuzumab after diagnosis of BM survived longer than expected. This finding justifies an active therapeutic approach: disease progression within central nervous system does not preclude benefit from trastuzumab treatment.
PMID: 18525303 [PubMed - indexed for MEDLINE]
Related Articles
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
[Breast. 2006]
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
[Onkologie. 2005]
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
[J Neurooncol. 2007]
Breast cancer subtypes and survival in patients with brain metastases.
[Breast Cancer Res. 2008]
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
[Cancer. 2003]

[StephN]

I thought that the benefit for staying on Herceptin would be that it may keep the cancer from getting active in the rest of the body. Thereby lessoning the chances that more brain mets would appear.

If the circulating tumor cells are greatly diminished then they have much smaller chance to lodge in the brain, even though the Herceptin molecule is too large to pass into the brain.

BTW - those survival rates seem kind of puny compared to what we know of the members of this board.